UniQure dips after share sale swells to $225 mln

Stifel Financial

24/06/2026 17:11

** U.S.-listed shares of Dutch drugmaker uniQure NV QURE.O down 1.1% to $48.51 on Weds after $225 mln follow-on offering priced 
** QURE sold ~4.9 mln shares at $45.50, a 7.2% discount to stock's last sale on Tues
** Offering size increased from $150 mln
** QURE shares surged 78% last Weds after U.S. FDA reversed its earlier position and said it will accept existing trial data for an accelerated review of co's Huntington's disease therapy, AMT-130
** QURE intends to use net offering proceeds to fund potential commercial launches of AMT-130, and to develop other product candidates, among other purposes, per the prospectus 
** Leerink Partners, Stifel, Guggenheim and RBC acting as joint bookrunners
** U.S.-listed shares have doubled YTD. They were trading around $14 a year ago
** 13 of 15 analysts rate the shares "strong buy" or "buy", 2 "hold"; median PT $60.50, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))